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a  b  s  t  r  a  c  t
A case of Berardinelli-Seip syndrome, a congenital generalised lipodystrophy, is reported.
Symptoms ﬁrst appeared when the patient was 20 years old. She showed severe insulin
resistance as well as micro- and macro-angiopathic complications, including chronic kidney
disease, which required renal replacement therapy with peritoneal dialysis. The patient’s
clinical course was reviewed since paediatric age (when initial signs of the disease being
already evident) to present time. Berardinelli-Seip syndrome is very uncommon, and the
present case is particularly rare because it is the only case (at least as reported in the
literature) in a patient receiving dialysis.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Se describe el caso de una paciente con síndrome de Berardinelli-Seip, un tipo de lipodis-
troﬁa congénita generalizada, que inició a los 20 an˜os, con marcada resistencia insulínica y
complicaciones micro- y macroangiopáticas, entre ellas una enfermedad renal crónica que
la  ha llevado a iniciar tratamiento renal sustitutivo en la modalidad de diálisis peritoneal.
Para  ello llevamos un repaso de la historia de la paciente desde la edad pediátrica (momento
en  el que ya aparecen los primeros signos de la enfermedad) hasta la actualidad. Más allá
de  lo infrecuente de esta enfermedad, es de destacar que lo excepcional del caso es que seal me s registrado en la literatura) de pacientes afectos de síndrometrata  del único caso (de  Berardinelli-Seip en pr
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Introduction
Berardinelli-Seip syndrome is an extremely rare disorder that
belongs to other group of congenital generalised lipodys-
trophies. The lipodystrophies are a heterogeneous group of
diseases, which can be congenital or acquired, characterised
by a partial or total absence of adipose tissue, along with
insulin resistance, hypertriglyceridemia, low HDL cholesterol,
liver disease, and renal disease, with proteinuria usually
in the nephrotic range, and increased cardiovascular risk.
They can be classiﬁed into generalised/localised and congen-
ital/acquired. The most prevalent form is acquired (localised
or generalised), secondary to anti-HIV antiretroviral therapy.
Berardinelli-Seip syndrome was ﬁrst described in 1954 by
Berardinelli1 in 2 children, and in 1959 by Seip2 in 3 more
patients. It has an autosomal recessive transmission and a
prevalence of 1/10 000 000.3 The syndrome can be caused by 3
characteristic mutations: type 1 is caused by a mutation in the
AGPAT2 gene (on exon 9q34), which codes for the enzyme 1-
acylglycerol-3-phosphate O-acyltransferase 2; type 2 is caused
by a mutation in the BSCL2 gene (on exon 11q13), which codes
for the protein seipin (and is generally associated with a worse
prognosis); and type 3 is due to a mutation resulting in altered
synthesis of the membrane protein CAV1. Ninety-ﬁve percent
of patients have one of the ﬁrst two mutations.
The disease is characterised by an almost complete
absence of adipose tissue, from birth, affecting practically the
entire body. It is associated with insulin resistance (it can
lead to the development of diabetes), dyslipidaemia (due to
hypertriglyceridemia and low HDL), hepatic steatosis, muscu-
lar pseudohypertrophy (Fig. 1), acromegalic features (Fig. 2)
and accelerated growth, acanthosis nigricans, and reduced
concentrations of leptin and adiponectin. All these conditions
accelerate the process of atherosclerosis and the develop-
ment of cardiovascular disease with microangiopathic and
macroangiopathic complications. Furthermore, up to 25% of
patients have hypertrophic cardiomyopathy.4,5Occasionally, patients develop chronic kidney disease
(CKD). This is probably related to the presence of dia-
betic nephropathy, although (as with other lipodystrophies)
Fig. 1 – Thoracic muscular pseudohypertrophy.Fig. 2 – Acromegalic features.
an association has also been described with focal scle-
rosing glomerulopathy and with membranoproliferative
glomerulonephritis.6–9
Due to its low prevalence, there is scarce information of
Berardinelli-Seip syndrome in the literature. To the best of our
knowledge, there have been few cases that developed CKD,
and no described cases of patients on peritoneal dialysis. It
should be noted that whilst the deﬁnitive diagnosis of this
disease is with the detection of a mutation, the complete
lack of adipose tissue along with muscular hypertrophy in the
absence of other criteria is also sufﬁcient for the diagnosis.
Clinical  case
We present the case of a patient born in 1961, with no history
of consanguinity or lipodystrophy. At 6 years old, she under-
went umbilical hernia repair, at which time she was noted to
have hepatomegaly of 2 cm (with no further investigation at
that time). At 11 years old, she was diagnosed with asymp-
tomatic multinodular goitre, and serial follow-up ultrasound
studies were performed. In 2002, she underwent surgery for
airway compression and has had hormone replacement ther-
apy since then. At 20 years old, she had a non-functioning
pituitary adenoma; an acromegaly screen was performed (due
to the patient’s then acromegalic features): somatomedins and
growth hormone stimulation test were normal.
The cardinal clinical symptoms of diabetes mellitus began
at puberty; raised peptide C and marked insulin resistance
conﬁrmed this. From the time of diagnosis, her diabetes did
not respond well to treatment, remaining poorly controlled
despite high doses of insulin (up to 5 IU/kg) and several oral
antidiabetics. Glycosylated haemoglobin (HbA1c) has always
been poorly controlled, reaching up to 13%. She has signiﬁ-
cant macroangiopathic and microangiopathic complications,
with chronic lower limb ischaemia (Fontaine stage III–IV) that
has led to multiple phalangeal amputations in both feet (2003,
2004, 2007, and 2014). She also has grade I–II retinopathy and
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arked peripheral neuropathy (diagnosed in 2000), which over
ime has become disabling, and since 2008 she has been mobi-
ising using a wheelchair. In addition, over the years, it became
vident that she had detrusor hypotonia (attributed to diabetic
europathy), leading to megabladder, grade I vesicoureteric
eﬂux, and recurrent urinary tract infections.
At age 38 years, she was noted to have abnormal liver func-
ion tests; therefore in 2002, she underwent a liver biopsy. A
iagnosis was made of Child–Pugh stage A cirrhosis secondary
o hepatic steatosis, with portal hypertension and devel-
pment of oesophageal varices without bleeding episodes.
reatment with propranolol was started. She had one episode
f hydropic decompensation in 2008 that resolved with con-
ervative treatment.
Another associated problem was the onset of leukope-
ia and thrombocytopenia that became persistent. She was
ssessed by the haematology team who performed a bone
arrow biopsy in 2002, which was reported as normal; the
icytopenia was attributed to hypersplenism secondary to
ortal hypertension.
It was in 2005 that the possibility of Berardinelli-Seip syn-
rome was raised (in view of the multiple diseases she had
resented with over the years). Therefore, a genetic study
as performed. Unfortunately, for technical reasons, it was
ot possible to sequence exon 4 of the BSCL2 gene. In the
ther 11 exons, there were no mutations. The conclusions
f the geneticists was that she must have a deletion of
his exon. Despite no mutation being found, the diagno-
is of Berardinelli-Seip syndrome was established, based on
he publication by Garg,4 which stated that even if a muta-
ion in the genes described above is not detected, patients
ho  meet the essential criteria of a generalised lack of
ody fat and hypermuscularity from birth can be given this
iagnosis.
This patient was referred to our endocrinology outpatient
epartment in 2008 for nephrotic proteinuria (of up to 6 g/24 h),
ith normal renal function, and normal immunology (except
or a mildly elevated IgA). Urinalysis and urinary sediment
ere unremarkable, and abdominal ultrasound showed kid-
eys of normal size with pelvicalyceal dilatation. At that
ime, renal biopsy was not performed and the clinical signs
ere attributed to diabetic nephropathy. It was decided then
o block the renin–angiotensin–aldosterone system with an
RB, and no further investigations were performed at that
ime. Renal function remained stable until June 2012, when,
ith no particular trigger, serum creatinine rose to 2.8 mg/dL,
nd creatinine clearance fell to 9 mL/min, with a protein-
ria of 4 g/24 h. Serum and urine immunoﬁxation detected
n IgG kappa and an IgG lambda component, which was
ttributed to a polyclonal gammopathy of undetermined
igniﬁcance. It was then that the diagnostic doubt arose
etween probable diabetic nephropathy, membranoprolifer-
tive glomerulonephritis (associated with Berardinelli-Seip
yndrome, but seemingly unlikely given the unremarkable
ediment), focal segmental glomerulonephritis associated
ith vesicoureteric reﬂux, and hepatorenal syndrome associ-
ted with cirrhosis. At that time, the possibility of performing renal biopsy was assessed, but ruled out due to the marked
hrombocytopenia and the fact that it was unlikely to change
er management; the condition was managed conservatively.(5):493–496 495
A recent transthoracic echocardiogram showed hypertrophic
cardiomyopathy with signs suggestive of fatty inﬁltration,
compatible with the expected ﬁndings in this disease.
The patient was admitted again in 2013 due to worsen-
ing renal function with no obvious cause, but with marked
uraemic symptoms in the form of nausea and vomiting that
lead to her starting renal replacement therapy. A peritoneal
high ﬂow swan-neck catheter (Fresenius Medical Care®) was
surgically placed by the general surgery team without com-
plications. After a month, she started continuous ambulatory
peritoneal dialysis with biocompatible solutions, which she
tolerated and adapted to well.
The dialysis schedule included three exchanges daily, one
with a low glucose concentration, another with icodextrin,
and the third with amino acids to minimise the risk of
malnutrition. Since then she has had acceptable Kt/V and
adequate volume management, maintaining a residual diure-
sis of around 1500 mL/day. Since starting this technique, the
only incidents have been one episode of peritoneal infection
due to staphylococcus epidermidis, which resolved with speciﬁc
AB treatment, and amputation of the ﬁrst right toe due to
ischaemia/necrosis.
Conclusions
We  presented this case because it seemed important for sev-
eral reasons, including the low prevalence of the disease itself
and the lack of published cases of Berardinelli-Seip syndrome
during renal replacement therapy. This case was an example
of how, even in patients with a poor survival prognosis, appro-
priate management of CKD (ﬁrst in outpatients and then in
our unit for advanced CKD) and the option of non-aggressive
techniques can offer patients a good quality of life (based on
quality of life questionnaires such as Euroquol and SF-36).
No speciﬁc treatment for Berardinelli-Seip syndrome was
given; we  aimed to control the different problems arising over
the course of the disease. This involved using lipid-lowering
therapy, dietary measures, cosmetic surgery, and, of course,
dialysis.
The usefulness of treatment with leptins (r-met-Huleptin)
in patients with lipodystrophy has been described, achiev-
ing a reduction in HbA1c, hypertriglyceridaemia, and hepatic
volume, and normalising the caloric proﬁle, as well as increas-
ing satiety (all in the space of 4 months). However, there
are no randomised studies that reliably demonstrate its
usefulness.10,11 Nonetheless, in our patient, given the marked
abnormality in carbohydrate metabolism, the endocrinology
team in our hospital completed the necessary application
procedures to the National Institute of Health (NIH) to begin
treatment with leptin. However, the supply of this drug was
denied, because at that time, the use of recombinant leptin
was not indicated in Berardinelli-Seip syndrome.Conﬂicts  of  interest
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